한빛사논문
Jan W. Buikema1,2,16, Soah Lee1,16, William R. Goodyer1,3,17, Renee G. Maas2,17, Orlando Chirikian1,17, Guang Li1, Yi Miao5, Sharon L. Paige1,3, Daniel Lee1, Haodi Wu1, David T. Paik1, Siyeon Rhee4, Lei Tian1, Francisco X. Galdos1, Nazan Puluca1, Benjamin Beyersdorf1, James Hu1, Aimee Beck1, Sneha Venkamatran1, Srilatha Swami6, Paul Wijnker7, Maike Schuldt7, Larissa M. Dorsch7, Alain van Mil2, Kristy Red-Horse1,4, Joy Y. Wu6, Caroline Geisen8, Michael Hesse8, Vahid Serpooshan1,9, Stefan Jovinge10,11, Bernd K. Fleischmann8, Pieter A. Doevendans2,12, Jolanda van der Velden7, K. Christopher Garcia5, Joseph C. Wu1,13,14,15, Joost P.G. Sluijter2, Sean M. Wu1,14,15,18,*
1Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA
2Utrecht Regenerative Medicine Center, Circulatory Health Laboratory, University Utrecht, Department of Cardiology, University Medical Center Utrecht, 3508 GA Utrecht, the Netherlands
3Division of Pediatric Cardiology, Department of Pediatrics, Stanford School of Medicine, Stanford, CA 94305, USA
4Department of Biology, Stanford University, Stanford, CA 94305, USA
5Department of Molecular and Cellular Physiology, Howard Hughes Medical Institute, and Department of Structural Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
6Division of Endocrinology and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
7Amsterdam Cardiovascular Sciences, Department of Physiology, Amsterdam University Medical Centers, Amsterdam, the Netherlands
8Institute of Physiology I, Life and Brain Center, Medical Faculty, University of Bonn, 53105 Bonn, Germany
9Department of Biomedical Engineering, Emory University and Georgia Institute of Technology, Atlanta, GA 30322, USA
10DeVos Cardiovascular Research Program of Spectrum Health and Van Andel Research Institute, 100 Michigan Street NE, Grand Rapids, MI 49503, USA
11Michigan State University, College of Human Medicine, 15 Michigan Street NE, Grand Rapids, MI, USA
12Netherlands Heart Institute, Holland Heart House, 3511 EP Utrecht, the Netherlands
13Department of Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA
14Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
15Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
16These authors contributed equally
17These authors contributed equally
18Lead Contact
*Corresponding author
Abstract
Modulating signaling pathways including Wnt and Hippo can induce cardiomyocyte proliferation in vivo. Applying these signaling modulators to human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in vitro can expand CMs modestly (<5-fold). Here, we demonstrate massive expansion of hiPSC-CMs in vitro (i.e., 100- to 250-fold) by glycogen synthase kinase-3β (GSK-3β) inhibition using CHIR99021 and concurrent removal of cell-cell contact. We show that GSK-3β inhibition suppresses CM maturation, while contact removal prevents CMs from cell cycle exit. Remarkably, contact removal enabled 10 to 25 times greater expansion beyond GSK-3β inhibition alone. Mechanistically, persistent CM proliferation required both LEF/TCF activity and AKT phosphorylation but was independent from yes-associated protein (YAP) signaling. Engineered heart tissues from expanded hiPSC-CMs showed comparable contractility to those from unexpanded hiPSC-CMs, demonstrating uncompromised cellular functionality after expansion. In summary, we uncovered a molecular interplay that enables massive hiPSC-CM expansion for large-scale drug screening and tissue engineering applications.
논문정보
관련 링크
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기